Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379Update on HER1-3 in advanced non-small-cell lung cancerCombating acquired resistance to tyrosine kinase inhibitors in lung cancerALK mutations conferring differential resistance to structurally diverse ALK inhibitors.ROS1 rearrangements define a unique molecular class of lung cancers.Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusionsMelanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.Characteristics of lung cancers harboring NRAS mutationsRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsGuiding Oncology Patients Through the Maze of Precision Medicine.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panelTargeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancerRationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerThe role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomasOptimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasShades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung CancerEGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to AfatinibTranslating genomic information into clinical medicine: lung cancer as a paradigm.RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome.Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.EGFR Fusions as Novel Therapeutic Targets in Lung CancerMy Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information.Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Lung cancer in 2010: One size does not fit all.Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
P50
Q24315969-78EDCCF1-AF43-4837-A479-255EE4D9537BQ26824058-FE03AE0F-2A6D-49C5-B529-308D11AB87E8Q26824877-DC594A77-4248-4F46-8D36-EEF289BDBE5FQ27851672-7F68EDEC-DBDF-43D4-8F73-37C0B0C23CA5Q27851700-56403881-2AFF-4DF1-88C5-39EC08ECB42AQ27851880-1DAF47D1-FEAE-4E8B-A9E5-4EB89BBB80B9Q27853012-D742C9E6-97C5-4783-8A44-A3DD62B106D2Q27853331-EDCE1B30-0C4D-4DB4-94F3-A1A0E9836DEEQ28706226-77517D5A-1314-4B23-B921-C02F61EB8939Q28730438-991241A4-483F-46E0-8EC4-551DFE122AFCQ30773132-CF5160DF-02C9-40AA-A884-323B932F79B1Q33560928-4EC506A9-7045-4ECE-ADF1-E47831690232Q33699641-D6026C60-AF63-45CF-BC96-BBA4A53F0FBBQ33860904-D51A4B35-F614-41BA-AEFE-172DDEC4CF1FQ34045543-6F27C09A-6BDE-4B28-992F-C87360D5671DQ34118710-C039CC16-0FD7-46D4-AB62-4785029E88CAQ34156513-0839ED8D-BD44-4D66-87C1-F33B6CA81972Q34694988-2FF0D967-FDBA-4664-B503-06CB45B62C41Q35112467-EEA1E273-7AEA-418F-A8A7-5C23B5B68454Q35112834-F053188E-0060-407D-A092-6C51214B860DQ35154039-BD3D3744-ACCC-4710-8608-45C93F4D49D7Q35462978-14E195E7-7643-4BE4-9DB8-9DA01BEA6A8CQ35775729-7D759095-3D26-496F-834C-292FC71884C7Q35844624-114608D5-D99C-44B0-BCC5-FAE0196E6254Q36244968-1159FE94-3FDF-4A0A-957B-2B1E3733EB8AQ36354845-A2D394F0-5CD2-4DBD-AFB7-E033E15D6A1BQ36525647-A3ECF051-E500-4C76-AD35-69D44D9B11EFQ36804705-1DC6C557-95DD-4CD2-AE9C-9214B9C885C8Q36920304-40FE856B-F903-48E5-8A3F-180528EB8ED3Q36971209-743D1EC4-4CAB-4EC4-870F-EA9C130908B3Q37211225-089EFCDB-98E8-4016-8EED-74790AF3B2F9Q37350770-CAFF4DB4-2DB2-44BD-9DF1-BDDD632FCDB7Q37590339-DCA1817E-F74A-4B67-8F9B-B18FEA088F62Q37592115-596DCAC3-C07A-4AC6-8536-14E05C64C8BBQ37833499-BDCCFE05-D77B-4C35-A870-C73F7C24F8E8Q38208748-D1F1F639-FCF5-4191-BCDB-41F9EAAB55B7Q38258948-25B54BDF-4A4F-4A4B-AC09-B33302208C7CQ38377528-A276A7FC-CCD5-42D4-8B01-4906AC99FC2CQ38484053-83C7DD7B-C409-4175-8816-94312211331FQ38805633-1FF0A3A3-9637-42FD-8539-6DB591A2BA50
P50
description
American oncologist
@en
wetenschapper
@nl
name
Christine M. Lovly
@en
Christine M. Lovly
@nl
type
label
Christine M. Lovly
@en
Christine M. Lovly
@nl
altLabel
Christine M. Lovly
@en
prefLabel
Christine M. Lovly
@en
Christine M. Lovly
@nl
P101
P106
P1960
waRMOr0AAAAJ
P21
P31
P496
0000-0002-3641-6361